1,25-dihydroxy-vitamin D3: a new treatment for hypoparathyroidism.
Eleven subjects aged four to 76 years with primary hypoparathyroidism have been treated with 1,25-dihydroxycholecalciferol (1,25-D3). Five subjects were not on vitamin D analogues before starting this drug. 1,25-D3 was found to be an effective treatment and a rapid biochemical response to dose adjustments was observed. In two subjects hypercalcaemia and reversible renal failure occurred. Thiazide-type diuretics necessitated dose reductions in a further two subjects. A scheme for starting hypoparathyroid subjects on this treatment is suggested. The need for regular biochemical assessment and awareness of possible drug interactions is emphasised. It is felt that 1,25-vitamin D3 has practical advantages over traditional forms of vitamin D in the treatment of hypoparathyroidism.
D000328:Adult; D000368:Aged; D002117:Calcitriol; D002675:Child, Preschool; D004100:Dihydroxycholecalciferols / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D006996:Hypocalcemia / Q000517:prevention & control; D007011:Hypoparathyroidism / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D004100:Dihydroxycholecalciferols; D006887:Hydroxycholecalciferols; D002117:Calcitriol